Since Merck is going to loose the ability to obtain some reagents that it uses in release assays, I am working in a small group of people testing reagents to see if they are sutible replacements reagents for GMP release assays for Varicella, Measles, Mumps, and Rubella vaccine products.

Worked in the Immuno-Oncology group on projects involving the tumor Micro environment. Examining the effects of small molecules on primary cells and how they might make tumor cells more susceptible to cell death.

Transfected CHO or HEK 293 cell lines in order to generate antigen expressing cell lines for high throughput screens by our robotics group. Analyzed established cell lines from ATCC for expression of target antigens. Sorted cell lines using BD FacsAria cell sorter. Generated cell lines with enhanced antigen profiles for use in Toxicity assays. Large scale transfections of 293 Expi Cells generating Humanized IgG molecules or Antigens for future toxicity assays. Determined toxicity of Antibody/drug conjugates against Lymphoma lines.  Screened cell lines for Antigen expression by FACS. Sorted human cell lines to produce target cells with higher antigen expression.  Performed internalization assays of IgG’s that were primary drug candidate leads, binding assays to rank antibody affinities by using Forte Bio's Octet, Epitope mapping of antibody leads using Forte Bio’s Octet.

Supported internal R&D efforts by screening cell lines for antigen expression. Developed FACS based assays for toxicity/viability. Elisa screening of hybridoma lines for antigen affinity. Developed a training module for our parent company in japan explaining our morphogene technology platform. Toxicity assay development to determine which antibody hits elicit ADCC or CDC activity in order to elicit an immune response to target cancer cells invitro.  Determined which antibody hits were antigen specific for target cell lines. Screened for ADCC and CDC activity among antibody candidates that had the best antigen affinity. Ranked Mabs accordingly based on if they elicited ADCC activity, CDC activity or both in an attempt to develop Mabs that elicited a targeted immune response. On the one year anniversary of being bought out by EISAI Pharmaceuticals, spent two months at parent R&D facility in Tsukuba Japan doing tech transfer of proprietary Morphogene technology (2008). Aided Japanese coworkers in the R&D labs in Tsukuba to start the process of mutating cells for gastro intestinal research projects.

Supported internal R&D efforts by screening cell lines for antigen expression. Elisa screening of hybridoma lines for antigen affinity. Toxicity assay development to determine which antibody hits elicit ADCC activity or CDC activity in order to elicit an immune response to target cancer cells invitro.  Scaled up Hybridoma lines, generated antibody’s for screening of drug candidates.  Developed Luminescence based ADCC and CDC assay to screen antibody candidates for Immune response.  Screened multiple lots of Complement and donor PBMC’s in order to have reproducibility in our ADCC and CDC assays.

Utilized Morphotek’s proprietary technology to mutate organisms for outside clients in order to generate cell lines with a desired phenotype.  Transfected cells with Morphogene to mutate cell lines.  Screened cells for rate of mutation by HPRT assay.  Checked for Morphogene expression by western blot. HTS screened cells for desired phenotype. Client provided a cell line that was making a humanized IgG that was a possible drug candidate. Generated cell line that overproduced IgG for manufacturing the monoclonal Mab.

Utilized Morphotek’s proprietary technology to mutate organisms for outside clients in order to generate cell lines with a desired phenotype.  Transfected cells with Morphogene to mutate cell lines.  Screened cells for rate of mutation by HPRT assay.  Checked for Morphogene expression by western blot. HTS screened cells for desired phenotype.  Generated cell lines that needed to be resistant to a Chemo Compound that was in preclinical development from client.

Worked in the Division of Infectious Diseases on projects that dealt with the neuro-pathogenic effects of HIV-1 in the CNS in order to find a way to eradicate persistent HIV infection once it crosses the blood brain barrier. Tissue culture, propagation of various HIV strains within a BL-3 safety environment, P24 ELISA quantification of neurotropic strains of HIV. Neuronal cell culture for invitro blood brain barrier model, immunocyto-chemistry, Pro-viral DNA extractions.